Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. - Test2 - elhamkhani - TriplyDB

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

http://www.wikidata.org/entity/Q30477320

about

Treatment Resistant Hypertension Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!Sleep-disordered breathing in heart failure: identifying and treating an important but often unrecognized comorbidity in heart failure patients The efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions.Resistant hypertension and untreated severe sleep apnea: slowly gaining insight Sleep and hypertension.Resistant hypertension and obstructive sleep apnea: the sparring partners Aldosteronism and resistant hypertension.Common secondary causes of resistant hypertension and rational for treatment Role of the kidneys in resistant hypertension Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea Effect of diuretics and sodium-restricted diet on sleep apnea severity: study protocol for a randomized controlled trial Effects of Heart Failure and its Pharmacological Management on Sleep.Role of obstructive sleep apnea in cardiovascular disease.Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis Effects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis.Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system.Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study Resistant hypertension, obstructive sleep apnoea and aldosterone.Resistant hypertension and obstructive sleep apnea in the setting of kidney disease Management of patients with resistant hypertension: current treatment options.The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment.Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.Vascular changes, cardiovascular disease and obstructive sleep apnea.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.Recent advancements in the treatment of resistant hypertension.Evaluation and pharmacologic approach to patients with resistant hypertension.Management of hypertension in the elderly.Pharmacotherapy of obstructive sleep apnea.Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea.Obstructive sleep apnea and hypertension: is the primary link simply volume overload?Aldosterone receptor antagonists: current perspectives and therapies The role of obesity and obstructive sleep apnea in the pathogenesis and treatment of resistant hypertension.Obstructive sleep apnea syndrome and chronic kidney disease: a new cardiorenal risk factor.Obstructive sleep apnea syndrome as a cause of resistant hypertension.

P2860

Q26775459-CBB5973B-69C6-4121-B622-C8FFC5BE2676 Q26776149-6FCFC687-09C2-45E4-B898-83892CD1C68F Q28681207-6A6354C4-0194-4271-82C6-CF813557D672 Q30428971-547F095F-4272-4E19-BE55-4D85ED615BE8 Q33933739-5AAEB9A5-85F8-4174-B04D-B6BC7D4302BD Q34035192-5FE6A4B3-F76B-4AE2-996A-6771A80606ED Q34512680-C5A7773B-59C2-4E04-85F5-A17763DDDA35 Q34557307-2B5782CF-C8A7-4F36-A7AE-FDCAB8A373CF Q34669789-CF5E926A-2253-4690-9146-26EC3C11FB06 Q34725369-5A01A24E-97DD-4831-BA9D-919BABFE6E23 Q34919512-888E0D8B-EF73-4EFB-8C21-34198BAFAA5E Q35321128-C11BB590-15CA-4BDC-8C40-78AF5F2D42C2 Q35544844-B02131F2-08AC-455C-AE6D-8D9180EB7BA4 Q35572665-E17A490A-25FF-4142-9992-836929ABBC35 Q35706912-50F9BD81-FB7E-4028-80EB-41708C9E1FB0 Q36072334-2B558D20-8705-45B5-86C8-162BE77C8810 Q36165729-461474C7-2223-46E7-B2FB-6AFB636CBFEE Q36740791-2F4D90B2-72A5-450D-B987-1166D41032C7 Q37039244-AF9479A3-5A70-4EE6-B69E-FAA5A07F6B37 Q37050292-52AC649C-01F2-4C14-8957-9C82BBD53ED3 Q37108921-7833BEB6-94B2-47D1-8A4B-90B2531F4294 Q37167764-DC8A630E-F80B-4C62-B5EA-5C41EACE0F53 Q37304418-EC24E541-B906-4FF1-951F-FF2F0255186E Q37479825-D0B56D7B-2CF3-4D44-A636-A3585E9680B2 Q37495691-FC11D3C3-5FC9-4001-97C0-1BBCA954D206 Q37811998-2475BFE3-DE2B-4771-8B22-D93A790D6519 Q37859758-C098FE16-2A87-4154-996F-25E9B1279062 Q37939427-6E200683-A82B-4599-8948-56042D821427 Q37976974-2D153DBB-EF71-4F16-A4D0-B5A8236EB713 Q37982210-411AACAE-F7DB-4C0B-AB4F-09A73412C1AD Q37982211-1EC51CC6-C97C-4F82-AF32-CA4BCD396D45 Q37992922-664486C7-26C5-47CF-97E9-FC2020257EB2 Q37994293-B2D84829-4E5D-455F-99DD-6AAB18BE6F9F Q38032789-7D4787AD-DB36-4C35-B1F2-3F81C5233552 Q38066462-B84EADD0-7C9A-4F14-BE1D-145C5B9AD34C Q38096919-FA488EDF-F9B1-4823-9A9C-441A034A2750 Q38120241-4AD6298C-D31C-4180-988E-816AD40E820A Q38172010-CB7A8C28-816A-4CB3-B2D5-F480C14375DE Q38179027-01A1C104-9510-42C2-B559-5092E3E9B6DD Q38209961-C41F47F7-BC3B-41A7-B6C0-B5A60D8D590D

P2860

Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

http://www.wikidata.org/entity/Q30477320

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Spironolactone reduces severit ...... tension: a preliminary report.

@ast

Spironolactone reduces severit ...... tension: a preliminary report.

@en

type

label

Spironolactone reduces severit ...... tension: a preliminary report.

@ast

Spironolactone reduces severit ...... tension: a preliminary report.

@en

prefLabel

Spironolactone reduces severit ...... tension: a preliminary report.

@ast

Spironolactone reduces severit ...... tension: a preliminary report.

@en

P1433

Q30477320-2646061A-59D0-4BB5-A560-789D6EAF6D50

P1476

Q30477320-0162CF96-353B-4C7C-B8A5-FC1BD157ABCD

P2093

Q30477320-01076303-0EF3-4234-92C6-5BF873672C11

Q30477320-722496A7-2427-48EB-86F0-9AF0FF33DC0B

Q30477320-8EC8528E-80BE-499F-9CC2-2537D033AEBE

Q30477320-92B8E0CC-D87B-4569-82CB-60AA47284667

Q30477320-B00D3F98-4952-49C7-832D-04C3FAAC5FF7

Q30477320-DA13D0C4-5722-4C3D-916D-3661E4A0B829

Q30477320-DDF13165-E5C5-45A9-BA97-5062AC3F2BEA

P2860

Q30477320-0B83757C-8026-45B7-8150-14F0CD9D9D1B

Q30477320-12243B8A-F854-4A93-80BA-B8CCBFAC0931

Q30477320-3DF1F4BB-DBE7-447F-9BB2-08EE0FACF4C9

Q30477320-52329F76-1CF3-4831-ADBA-48DE1EE97DE6

Q30477320-53041745-505B-4A27-8E62-7A870E16C6A1

Q30477320-540CC4FE-C470-407D-AB99-BF12F5FF98A6

Q30477320-5A0E8A89-513A-44DC-BBF1-0C9EF9368B5D

Q30477320-5AB5FC4C-B344-4486-BF3A-D7DD394D6D60

Q30477320-62BB324C-4C92-4611-AD17-3058BD128A3F

Q30477320-6BC6DEC9-DFA0-4B3A-A68C-6B0CB5A87CE1

P2888

Q30477320-77AC8DC7-737B-401B-9F91-A7AE3374E80B

P304

Q30477320-9C65BDE0-2E0E-4C0B-8CA1-B49FEF1AF785

P31

Q30477320-92B7B993-B1DB-4C0B-985B-2A2B8AB68CB1

P356

Q30477320-5C5B9858-BA84-478C-AB86-A890F30DC310

P433

Q30477320-DDF3997F-263D-4BE1-931E-5EA438BDF01F

P478

Q30477320-1492088E-64BC-46FC-A9DB-CEBCD0A6A792

P577

Q30477320-FFBE418E-FCEA-4139-8B76-9FC2259F5018

P5875

Q30477320-998BB257-8118-494A-9EB6-88E0FA18E8BA

P6179

Q30477320-DEEA768D-11DE-4B49-953D-5C7E86A9433B

P698

Q30477320-5F4A9489-18EA-4F9A-88A6-3973CD84BC2B

P921

Q30477320-0BA68724-FDC0-4FA8-BEE5-D57F8AC31DEA

Q30477320-B7C4447E-DC7B-4AC1-BA73-32344C1B790D

P932

Q30477320-9F5D8A7F-A7A8-493A-8ADA-A876D417DDA2

P356

P1433

Journal of Human Hypertension

P1476

Spironolactone reduces severit ...... tension: a preliminary report.

@en

P2093

D A Calhoun

http://www.w3.org/2001/XMLSchema#string

E Pimenta

http://www.w3.org/2001/XMLSchema#string

K Gaddam

http://www.w3.org/2001/XMLSchema#string

S J Thomas

http://www.w3.org/2001/XMLSchema#string

S M Harding

http://www.w3.org/2001/XMLSchema#string

S Oparil

http://www.w3.org/2001/XMLSchema#string

S S Cofield

http://www.w3.org/2001/XMLSchema#string

P2860

High prevalence of unrecognized sleep apnoea in drug-resistant hypertension

Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard

Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study

Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects.

Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis.

Obstructive sleep apnea as a risk factor for stroke and death.

Sleep apnea and hypertension: interactions and implications for management.

Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea.

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion

Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

P2888

P304

532-537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JHH.2009.96

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40693897

http://www.w3.org/2001/XMLSchema#string

P6179

1044428967

http://www.w3.org/2001/XMLSchema#string

P698

20016520

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

2891919

http://www.w3.org/2001/XMLSchema#string